Senographe Pristina 3D
GE Healthcare · Decision date Nov 21, 2025
What did the FDA approve?
FDA records P130020/S005 as a supplement to PMA P130020, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 21, 2025.
FDA approval order statement
Approval for Senographe Pristina 3D that includes an update to the DBT reconstruction algorithm to enhance image quality using deep learning algorithms to correct sparse view artifacts, compensate for patient motion artifacts and enhance the visibility of soft tissue lesions within the 2D synthetic image.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Radiology
- Decision date
- Nov 21, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P130020/S005
- Regulatory pathway
- PMA supplement
- Applicant
- GE Healthcare
- Product code
- OTE
- Decision code
- APPR
- Decision date
- Nov 21, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Digital breast tomosynthesis.
- Applicant
- GE Healthcare
- Product code
- OTE
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130020/S005 received
Application receipt date recorded by FDA.
P130020/S005 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P130020. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code OTE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAMMOMAT B.brilliant with Tomosynthesis OptionP140011/S009 | Siemens Medical Solutions USA, Inc. | PMA supplement | Jul 1, 2026 | FDA |
Envision Mammography PlatformP080003/S011 | Hologic, Inc. | PMA supplement | Nov 24, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
GE Healthcare
- Headquarters
- Not reported
- Brand website
- gehealthcare.com
- FDA applicant address
- 3000 N. Grandview Blvd., Waukesha, WI, 53188
Sources and methodology
- Original FDA record: P130020/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
